Candida auris infections in China

Han Du,Jian Bing,Clarissa J. Nobile,Guanghua Huang
DOI: https://doi.org/10.1080/21505594.2022.2054120
IF: 5.428
2022-04-20
Virulence
Abstract:First described in 2009 in Japan, the multidrug-resistant human fungal pathogen Candida auris represents a new global public health threat [1,2]. As of February, 2021, C. auris cases have been reported in over 40 countries across six continents, with several outbreaks occurring simultaneously in different hospitals [3–6]. C. auris is often called a "superbug" due to its multidrug-resistant and highly transmissible features. Some clinical isolates are even resistant to all three of the major classes of antifungal drugs (the azoles, the polyenes, and the echinocandins) [2,7]. In 2019, the Centers for Disease Control and Prevention (CDC) placed C. auris on the list of urgent threats (Antibiotic Resistance Threats in the United States, 2019; https://www.cdc.gov).
microbiology,immunology,infectious diseases
What problem does this paper attempt to address?